International guidelines agree that family-based lifestyle changes are foundational for pediatric obesity, with GLP-1 receptor agonists like semaglutide and liraglutide recommended as add-on therapy for severely obese adolescents.
4 Major Guidelines ComparedAAP, WHO, NICE, and Polish frameworks all now include GLP-1 receptor agonists as adjunctive therapy options for adolescents with severe obesity
What the researchers found
Across guidelines from the AAP, WHO, NICE, and Polish pediatric bodies, GLP-1 receptor agonists — specifically liraglutide and semaglutide — are now recommended as adjunctive pharmacotherapy for carefully selected adolescents with severe obesity and significant comorbidities. Family-based lifestyle intervention remains the cornerstone of care across all frameworks, but the review reveals clinically important differences in diagnostic thresholds, risk stratification approaches, and comorbidity screening recommendations between organizations.
Why it matters
Childhood obesity rates continue to rise globally, and GLP-1 receptor agonist peptides represent one of the most promising pharmacological advances for treatment. This review helps clinicians understand where international guidelines agree and differ on when to escalate from lifestyle changes to medications like semaglutide, which is especially important as these peptide therapies become more widely available for adolescent patients.
How the study worked
The researchers conducted a narrative review comparing current international and national guidelines for pediatric obesity management. They analyzed recommendations from the American Academy of Pediatrics (AAP), World Health Organization (WHO), UK National Institute for Health and Care Excellence (NICE), and the Polish pediatric position statement, along with other European consensus documents. They also summarized key biological mechanisms relevant to clinical assessment and treatment decisions.
What this study cannot tell us
As a narrative review rather than a systematic review, the study selection may not be comprehensive. The focus on Polish practice may limit generalizability to other healthcare systems. The review does not include original patient data or meta-analyses of treatment outcomes, so it cannot directly quantify the effectiveness of different approaches.
How to read the evidence
This is a narrative review that synthesizes existing guidelines and recommendations rather than presenting original clinical data. While it provides a useful comparative framework, narrative reviews are subject to selection bias and do not carry the same evidence weight as systematic reviews or randomized trials.
When this study was published
Published in 2026, this review reflects the most current international guidelines and includes recent updates on GLP-1 receptor agonist approvals for adolescent obesity treatment.
The bigger picture
This review arrives at a pivotal moment in pediatric obesity treatment. GLP-1 receptor agonists, originally developed for type 2 diabetes, have transformed the obesity treatment landscape for adults and are now gaining formal guideline endorsement for adolescents. The comparison across international frameworks reveals a growing consensus around peptide-based pharmacotherapy while exposing implementation gaps, particularly in countries where access and reimbursement lag behind the evidence.
Questions still open
- How can healthcare systems in countries like Poland close the gap between guideline recommendations and actual access to GLP-1 therapies for adolescents?
- What are the long-term safety profiles of semaglutide and liraglutide when started during adolescence?
- Should diagnostic thresholds and screening criteria be harmonized across international guidelines to reduce variation in care?
Common questions
Are GLP-1 medications like semaglutide approved for use in children and teenagers?
What is the first-line treatment for pediatric obesity according to these guidelines?
Read the original research
Pediatric Obesity: Diagnostic and Therapeutic Approaches in the Context of International Guidelines With a Focus on Polish Practice.
Cureus, 18(1), e101545
Citation
Łuczak, Paweł M; Perediatkiewicz, Jakub; Liszka, Paweł; Puchalski, Konrad; Patrzykąt, Klaudia M; Olejnik-Chlewicka, Klaudia M; Urbański, Wojciech; Zasiadła, Marta; Brodowski, Jakub; Ogórek, Agata. (2026). Pediatric Obesity: Diagnostic and Therapeutic Approaches in the Context of International Guidelines With a Focus on Polish Practice.. Cureus, 18(1), e101545. https://doi.org/10.7759/cureus.101545